

SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Repository Corticotropin Medications - INFANTILE SPASMS (IS)

| <u>PREFERRED</u> | <u>NON-PREFERRED</u> |
|--|--|
| <input type="checkbox"/> Purified Cortrophin™ Gel (repository corticotropin) | <input type="checkbox"/> HP Acthar® Gel (repository corticotropin) *Member must have tried and failed preferred Purified Cortrophin™ Gel and meet all applicable PA criteria below |

****Acthar Gel single-dose pre-filled SelfJect injector is for subcutaneous administration by adults only.****

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

Note: (Neurology 2012;78:1974-1976) Class I study showed similar efficacy between low-dose (20-30 IU) and high dose (150 IU/m²) natural ACTH. Low dose ACTH should be considered as an alternative to high dose ACTH for treatment of infantile spasms. (Level B).

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

- Prescriber **MUST** be a Neurologist
- Member **MUST** have a documented diagnosis of Infantile Spasms
- Approval will only be granted for a **MAXIMUM** of **30 days only** due to similar adverse effects of corticosteroids. After 2 weeks of treatment, dosing should be gradually tapered and discontinued over a 2-week period. The following is one **suggested** tapering schedule:
 - 30 U/m² in the morning for 3 days; 15 U/m² in the morning for 3 days; 10 U/m² in the morning for 3 days; and 10 U/m² every other morning for 6 days.
- Complete the regimen below (**repository corticotropin is supplied as 5 mL multi-dose vial containing 80 USP Units per mL**):

Approval will be a **MAXIMUM** of **30 days only** (combined inpatient and outpatient time period)

| <u>Initial Dose Schedule</u> | <u>Approval at Outpatient pharmacy will be based on volume needed at discharge from hospital</u> | |
|---|--|--------------------------------------|
| 75 U/m ² BID x _____ days | TOTAL _____ mL x _____ # days (max 29 days) | |
| <u>Taper Dose Schedule</u> | | <u>BODY SURFACE AREA BSA</u> |
| 30 U/m ² QD x _____ days | _____ mL x _____ days | Weight: _____ kg |
| 15 U/m ² QD x _____ days | _____ mL x _____ days | Height/Length: _____ in. |
| 10 U/m ² QD x _____ days | _____ mL x _____ days | Calculated BSA: _____ m ² |
| 10 U/m ² QOD x _____ days | _____ mL x _____ days | |

TOTAL Number of vials needed: _____ /days (max 29 days)

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.